Authors
Bass E.J.1, Fiorentino F.2, Szigeti M.3, Klimowska-Nassar N.3, Sasikaran T.3, Jadav P.4, Rawlins F.1, Oblak M.5, Khoubehi B.6, Winkler M.1, Nasseri M.7, Pope A.8, Sokhi H.9, Dudderidge T.10, Arumainayagam N.11, Sydes M.R.12, Ahmed H.U.1, The PROSPECT Study Group13
Institutions
1Imperial Prostate, Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, 2Imperial Prostate, Imperial College London, Imperial Clinical Trials Unit, London, United Kingdom, 3Imperial College London, Imperial Clinical Trials Unit, London, United Kingdom, 4Imperial College London, Imperial College Trials Unit, London, United Kingdom, 5Chelsea and Westminster Hospitals NHS Foundation Trust, Dept. of Research and Development, London, United Kingdom, 6Chelsea and Westminster Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 7The Hillingdon Hospitals NHS Foundation Trust, Dept. of Research and Development, Uxbridge, United Kingdom, 8The Hillingdon Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 9The Hillingdon Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, 10University Hospital Southampton, NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, 11Ashford & St. Peter's Hospitals NHS Trust, Dept. of Urology, Chertsey, United Kingdom, 12University College London, MRC Clinical Trials Unit at UCL, London, United Kingdom, 13London, United Kingdom